A closer look at “Tango Therapeutics' Combo Therapy Yields 82% Tumor Response in Advanced Pancreatic Cancer ”, exactly as the source publishes it. Tango Therapeutics announced that its experimental drug combination achieved an 82% tumor response rate in patients with a specific type of advanced pancreatic cancer. The results, reported by STAT+, highlight a potential breakthrough for a disease with notoriously limited treatment options. The trial focused on patients whose tumors harbor certain genetic alterations, though the company did not disclose the exact biomarkers in the initial release.
Pancreatic cancer remains one of the deadliest malignancies, with a five-year survival rate below 13%, making any significant response rate a notable development. Tango's approach pairs a targeted therapy with an immune-modulating agent, aiming to enhance the body's ability to attack cancer cells. The 82% response rate far exceeds historical benchmarks for this patient population, where single-agent therapies often yield responses in less than 20% of cases. The full version stays on the original page, which this listing opens directly.